October is ADHD Awareness Month, and this year’s theme, “The Many Faces of ADHD,” highlights how differently the condition can look from one person to another. Dr. Jim Saperstone from Community Care ...

Source: Ryan S. Sultan, MD In July 2026, the FDA approved centanafadine, sold as Simtriyo, for ADHD. The trade coverage converged on two claims: that it's a first-in-class "triple reuptake inhibitor," ...

For years, adults seeking treatment for attention deficit hyperactivity disorder (ADHD) in New Zealand have faced a frustrating bottleneck. Public mental health services have had little capacity to ...

No one I talk to is happy with the state of health care. Doctors feel disempowered and pressured and do not have the time they want to spend with patients. And anyone who goes to see doctors feels ...